This will not have unduly affected the results, as irrelevant posts should have been filtered out by the zero-shot filter
[DOI] [PubMed] [Google Scholar] 65.zsoy Y., Gngr S., Cevher E
Sanofi Orexigen Therapeutics Amgen Johnson & Johnson Abbott Laboratories Takeda Pharmaceutical Company Zafgen Currax Pharmaceuticals Rhythm Pharmaceuticals Key Developments In September 2025, Eli Lilly announced plans to launch its experimental weight-loss pill, orforglipron, in India
Three studies had no control arm, eight studies were open-label, and eight studies included fewer than 100 participants
10.1016/j.bbamcr.2016.01.023 2
In contrast, the placebo group resulted in increased levels of IL-6 or the same levels of IL-6 in plasma ( Figure 4A )